Ohara C （ Mph ）, Murata A （ MD ）, Inoue M （ MD,PhD ）, Inoue K （ MD,PhD ） Persons with undiagnosed diabetes have worse profiles of cardiovascular and metabolic.

Slides:

Advertisements

Similar presentations

DO YOU HAVE THE METABOLIC SYNDROME? You're never too young to have it Jacqueline A. Eberstein, R.N.

Advertisements

Change in Abdominal Obesity & Risk of Coronary Calcification Siamak Sabour, MD, MSc, DSc, PhD, Postdoc Clinical Epidemiologist Persian International Epidemiology.

Metabolic Syndrome in Non-Diabetics Vilanova Fillat, M.B. Falguera Vilamajó, M. Garriga Badia, A. Miró Vallvé, N. Cebrian Aiguadé, C. Escardó Font, C Bacompte.

High-density lipoprotein subclasses in subjects with impaired fasting glucose Filippatos TD 1, Barkas F 1, Klouras E 1, Liontos A 1, Rizos EC 1, Gazi I.

ABSTRACT CONCLUSIONS BACKGROUND Heart Rate Recovery: An Indicator of Fitness Among Middle School Children Daniel Simhaee, Roopa Gurm, Susan Aaronson, Jean.

Factors associated with prediabetes in adult children of patients with premature coronary heart disease; the study of families of patients with premature.

Sugar-Sweetened Beverage Consumption and Incident Cardiovascular Risk Factors: The Multi-Ethnic Study of Atherosclerosis (MESA) Christina Shay PhD MA 1.

Insulin Sensitivity is Inversely Associated with Cardiovascular Disease Risk Factors in Adolescents with and without Type 1 Diabetes Brian J. Specht 1,

Ambulatory Blood Pressure Profiles in Adolescents with Type 1 Diabetes Andrew J. Ellis 1,2, B.A.; David M. Maahs 2, M.D. Ph.D.; Franziska K. Bishop 2,

METABOLIC Syndrome: a Global Perspective

Does the weight history of patients with newly diagnosed type 2 diabetes influence the weight changes after diabetes diagnosis? Niels de Fine Olivarius.

Low level of high density lipoprotein cholesterol in children of patients with premature coronary heart disease. Relation to own and parental characteristics.

The effects of initial and subsequent adiposity status on diabetes mellitus Speaker: Qingtao Meng. MD West China hospital, Chendu, China.

SERUM VISFATIN CONCENTRATION IS ASSOCIATED WITH AN ATHEROGENIC METABOLIC PROFILE T.D. Filippatos 1, A. Liontos 1, F. Barkas 1, E. Klouras 1, V. Tsimihodimos.

Diagnosis of diabetes. Diabetic symptoms Diabetic symptoms + venous sample for : –Random venous ≥ 11.1 mmol/l ( ) –Fasting glucose > 7(

Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]

Conclusion In conclusion, preliminary data from this nutrition intervention study suggest that a well balanced Mediterranean-type diet is able to reduce.

Organizational criteria for Metabolic Syndrome National Cholesterol Education Program Adult Treatment Panel III World Health OrganizationAmerican Association.

Risk of Type 2 Diabetes and It’s Complications Along The Continuum of Fasting Plasma Glucose Gregory A. Nichols, PhD Collaborative Diabetes Education Conference.

GDM-DEFINITION Gestational Diabetes Mellitus (GDM) is defined as ‘carbohydrate intolerance with recognition or onset during pregnancy’, irrespective of.

A Randomized Placebo- Controlled Trial of Metformin for the Treatment of HIV Lipodystrophy Rakhi Kohli MD MS, Christine Wanke MD, Sherwood Gorbach MD,

Diabetes National Diabetes Control Programme

Farid Saad Euro Weight Loss-2015 Frankfurt, Germany August 18 – 20, 2015.

High level of low density lipoprotein cholesterol in adult children of patients with premature coronary heart disease: relation to own and parental characteristics.

Prospective Urban and Rural Epidemiology Study PURE Patricio López-Jaramillo, MD, PhD Lina Patricia Pradilla MD National Coordinator Colombia.

Lesotho STEPS Survey 2012 Fact Sheet John Nkonyana Director Disease Control.

Lifestyle diseases in People living with HIV

CHAPTER 8: Blood Pressure Control and Dyslipidaemia in Patients on Dialysis S. Prasad Menon Hooi Lai Seong Lee Wan Tin Sunita Bavanandan Source: 21 st.

Dr. Nadira Mehriban. INTRODUCTION Diabetic retinopathy (DR) is one of the major micro vascular complications of diabetes and most significant cause of.

Date of download: 5/31/2016 From: Metabolic Risk Factors Worsen Continuously across the Spectrum of Nondiabetic Glucose Tolerance: The Framingham Offspring.

Risk of Progression to Type 2 Diabetes Based on Relationship Between Postload Plasma Glucose and Fasting Plasma Glucose Diabetes Division and the Clinical.

The short term effects of metabolic syndrome and its components on all-cause-cause mortality-the Taipei Elderly Health Examination Cohort Wen-Liang Liu.

Table 1 Descriptive Variables __________________________________________________________________________________________ Variables M (SD) Min. Max. n*

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Plasma triglycerides and type III hyperlipidemia.

Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.

CHAPTER 8: BLOOD PRESSURE CONTROL AND DYSLIPIDAEMIA S. Prasad Menon Hooi Lai Seong Lee Wan Tin Sunita Bavanandan Source: 20 th MDTR Report 2012, NRR.

METHODS INTRODUCTION I Webster, C Westcott, C Marincowitz, N Mashele, P De Boever, N Goswami, H Strijdom Division of Medical Physiology, Faculty of Medicine.

Presented by Slyter Nutrition Consulting Services.

PREVALENCE AND RISK FACTORS FOR NON- ALCOHOLIC FATTY LIVER DISEASE AMONG AN URBAN AGING ADULT SRI LANKAN POPULATION– RAGAMA HEALTH STUDY 7-YEAR FOLLOW.

analysed to establish the distribution of GJD2 SNPs T2D patients

Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study Dr Jack R W Brownrigg,

Retinopathy in Persons without Diabetes

Raw data Log-transformed data Male age log age Female age log age

Dietary patterns in a group of medical students

From ESH 2016 | POS 7D: Jan Rosa, MD

American Public Health Association Annual Meeting

Copyright © 2011 American Medical Association. All rights reserved.

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Insulin resistance in prepubertal children

BACKGROUND RESULTS OBJECTIVES METHODS CONCLUSIONS REFERENCES

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

Copyright © 2012 American Medical Association. All rights reserved.

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

α-Glukosidase-Inhibitors

Determinants of new onset diabetes among hypertensive patients randomised in the ASCOT-BPLA Trial Dr Ajay K Gupta International Centre for Circulatory.

Metabolic Syndrome (N=160) Non-Metabolic Syndrome (N=138) 107/53

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Comparison of Metabolic Abnormalities between PCOS Phenotypes A Hospital-based study LI Hui1,2 LI Lin2 YANG Dong-zi2＃ 1 Bupa Medical Center,

Health-promoting lifestyles and cardio-metabolic risk factors among international students in South Korea Chun-Ja Kim, PhD, RN, JeeWon Park, PhD, RN,

Sunjoo Boo, RN, PhD, Erika Sivarajan Froelicher, RN, PhD, FAAN

Baseline characteristics of CACTI type 1 diabetic subjects with cystatin C measurements (n=509), stratified by CAC progression status Maahs DM et al.

Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies The Emerging.

Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome Macarena Alpañés, M.D., Manuel.

Lars E. Laugsand et al. BTS 2016;j.jacbts

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

Glucose Metabolism in Patients with Essential Hypertension

HR for mortality in ischemic heart disease.

HR for myocardial infarction.

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Ohara C （ Mph ）, Murata A （ MD ）, Inoue M （ MD,PhD ）, Inoue K （ MD,PhD ） Persons with undiagnosed diabetes have worse profiles of cardiovascular and metabolic predictors than those with known diabetes. Undiagnosed diabetes should also be recognized as a condition with these risks. Table1 Subject Characteristics Figure1 Frequencies of subjects who had worse profiles of cardiovascular and metabolic markers according to the four categories Table2 Comparison of cardiovascular and metabolic markers between known and undiagnosed diabetes according to age (<60.5, ≧ 60.5 years) Table3 Comparison of cardiovascular and metabolic markers between known/poor control (HbA1c >=7.0%) and undiagnosed diabetes POINT ･ Table1&Figure1 ・ Table2 ・ Table3 Undiagnosed diabetes has worse profiles of cardiovascular and metabolic markers than known diabetes Tosa Danji （ MD, PhD), Tosa Danji （ MD, PhD), Department of Inoue Methods, Kada Medical Center, IM University School of Medicine, Japan IntroductionResults Methods Design: Setting &Period: Purpose of this study Discussion Conclusion Address: Doraemon-City, Tokyo, Japan N=23,491 NFG (Normal Fasting Glucose) FPG<100 N=23,491 NFG (Normal Fasting Glucose) FPG<100 N=8,786 IFG (Impaired Fasting Glucose ) 100 ≦ FPG ＞ 125 N=8,786 IFG (Impaired Fasting Glucose ) 100 ≦ FPG ＞ 125 N=63103 persons Excluded N=63103 persons Excluded N=34,282 persons Eligible for analysis N=34,282 persons Eligible for analysis N=97,585 persons Aged years April 1998 –march 2006 N=97,585 persons Aged years April 1998 –march 2006 N=1089 Undiagnosed Diabetes FPG ≧ 126 N=1089 Undiagnosed Diabetes FPG ≧ 126 N=795 Known Diabetes FPG ≧ 126 N=795 Known Diabetes FPG ≧ 126 Characteristics NFGIFG Known Diabetes Undiagnosed Diabetes P value adjusted by Sex Age BMI n ＝ n ＝ 8786n ＝ 916 n ＝ groups 2groups Known vs Undiagnose d Fasting plasma glucose (mol/l) 5.0± ±0.38.0±2.48.9±2.3<.0001 HbA1c (%) 4.8±0.45.2±0.56.9±1.67.1±1.8<.0001 Age (years) 49.8 ± ± ± ±10.4 Male sex, n (%) 9879 〈 42.1) 5779(65.8)650(71.3)781(71.7) BMI (kg/m2) 22.3± ± ± ±3.5 Systolic blood pressure (mmHg) 120±17131±18131±17137±19<.0001 Diastolic blood pressure (mmHg) 73±1180±1178±1083±11<.0001 Triglycerides (mmol/l) 0.93(0.67to1.35)1.24(0.89to1.79)1.33(0.92to1.85) 1.54(1.07to2.30) <.0001 Total cholesterol (mmol/l) 199.6± ± ± ± 38.1<.0001 HDL cholesterol (mmol/l) 59.1± ± ± ±12.7<.0001 Asparate aminotransferase (U/l) 20.0(17to24)22.0(19to27)22(18to27)24(19to31)<.0001 Alanine aminotransferase (U/l) 17(13to23)21(16to32)22(16to32)26(19to39)<.0001 γ -Glutamyltranspeptidase (U/l) 17(11to28)26(16to47)25(15to46)38(23to72)<.0001 Uric acid 5.1±1.35.8±1.45.4±1.35.6±1.4<.0001 Data are expressed as mean ± SD, median (25th percentile, 75th percentile) or number (%). For comparison of means, triglycerides, asparate aminotransferase, alanine aminotransferase, γ-glutamyltranspeptidase were log transformed for their skewed distributions. Age <60.5 years ≧ 60.5 years Known DM n=435 Undiagnosed DM n ＝ 580 P value Known DM n=479 Undiagnosed DM n=509 P value Fasting plasma glucose (mmol/l) 8.2±2.69.0±2.4 < ± ±2.2 <.0001 HbA1c (%) 6.8± ± ± ± BMI (kg/m2) 24.0± ± 3.8 < ± ± 3.1 <.0001 Systolic blood pressure (mmHg) 128.2± ± 19.3 < ± ± 18.3 <.0001 Diastolic blood pressure (mmHg) 77.8± ± 11.9 < ± ± 11.3 <.0001 Triglycerides (mmol/l) 1.74±1.62.1± ± ± 0.9 <.0001 Total cholesterol (mmol/l) 202.9± ± 40.0 < ± ± 35.5 <.0001 HDL cholesterol (mmol/l) 51.6± ± ± ± Asparate aminotransferase (U/l) 22(18to28)24(19to32) (18to26)23(20to29) Alanine aminotransferase (U/l) 24(17to38)29(20to44) < (16to28)32(19to55) <.0001 γ -Glutamyltranspeptidase (U/l) 30(18to58)46(27to90) < (14to35)32(19to55) <.0001 HbA1c Known DM n=355 Undiagnosed DM n=430 P value Fasting plasma glucose (mmol/l) 9.9± ±2.6<.0001 BMI (kg/m2)24.0± ± Systolic blood pressure (mmHg) 131.4± ± Diastolic blood pressure (mmHg) 78.1± ± Triglycerides (mmol/l)1.4(0.9to1.9)1.5(1.1to2.3)0.01 Total cholesterol (mmol/l)205.6± ± HDL cholesterol (mmol/l)51.2± ± Asparate aminotransferase (U/l) 21(17to29)23(19to30)0.04 Alanine aminotransferase (U/l) 22(17to37)27(19to39)0.009 γ -Glutamyltranspeptidase (U/l) 27(16to52)37(23to67)<.0001